KamadaKMDA
Mentioned
Impact on stocks 1
Health Care
KamadaKamada Reports Record Q2 2026 Revenue and Reiterates Guidance
EarningsManagement
Kamada reported record second-quarter 2026 revenue of $54.9 million, up 23% year-over-year, and reiterated its full-year guidance of $200 million to $205 million in revenue and $50 million to $53 million in adjusted EBITDA. First-half revenue reached $100.2 million, a 13% increase, with adjusted EBITDA of $25.7 million, up 14%, and net income of $13.4 million, up 18%. The company also announced that CFO Chaime Orlev will leave at the end of the year, and it has initiated a search for his successor. Kamada highlighted strong demand for KEDRAB, VARIZIG, and HEPAGAM, and expects initial sales under its new three-year $50 million plasma supply agreement to begin in the fourth quarter.
Kamada